JP7819893B2 - 慢性肺疾患を治療するための方法および組成物 - Google Patents

慢性肺疾患を治療するための方法および組成物

Info

Publication number
JP7819893B2
JP7819893B2 JP2020514518A JP2020514518A JP7819893B2 JP 7819893 B2 JP7819893 B2 JP 7819893B2 JP 2020514518 A JP2020514518 A JP 2020514518A JP 2020514518 A JP2020514518 A JP 2020514518A JP 7819893 B2 JP7819893 B2 JP 7819893B2
Authority
JP
Japan
Prior art keywords
months
weeks
igf
pma
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020514518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533344A5 (enExample
JP2020533344A (ja
Inventor
ノーマン バートン
アレクサンドラ マンジリ
Original Assignee
オーク ヒル バイオ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーク ヒル バイオ リミテッド filed Critical オーク ヒル バイオ リミテッド
Publication of JP2020533344A publication Critical patent/JP2020533344A/ja
Publication of JP2020533344A5 publication Critical patent/JP2020533344A5/ja
Priority to JP2023125304A priority Critical patent/JP2023145646A/ja
Priority to JP2025086115A priority patent/JP2025114869A/ja
Application granted granted Critical
Publication of JP7819893B2 publication Critical patent/JP7819893B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020514518A 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物 Active JP7819893B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023125304A JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
US62/557,113 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023125304A Division JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2020533344A JP2020533344A (ja) 2020-11-19
JP2020533344A5 JP2020533344A5 (enExample) 2021-11-11
JP7819893B2 true JP7819893B2 (ja) 2026-02-25

Family

ID=63794620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020514518A Active JP7819893B2 (ja) 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A Pending JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A Pending JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Country Status (21)

Country Link
US (3) US20190151411A1 (enExample)
EP (2) EP4663184A3 (enExample)
JP (3) JP7819893B2 (enExample)
KR (1) KR20200097679A (enExample)
CN (1) CN111432881A (enExample)
AU (2) AU2018328827B2 (enExample)
BR (1) BR112020004760A2 (enExample)
CA (1) CA3075482A1 (enExample)
CL (1) CL2020000597A1 (enExample)
CO (1) CO2020004244A2 (enExample)
EA (1) EA202090705A1 (enExample)
EC (1) ECSP20055797A (enExample)
IL (1) IL273174B2 (enExample)
MX (1) MX421623B (enExample)
MY (1) MY204825A (enExample)
PE (1) PE20201166A1 (enExample)
PH (1) PH12020500489A1 (enExample)
SG (1) SG11202002088TA (enExample)
UA (1) UA128690C2 (enExample)
WO (1) WO2019051474A1 (enExample)
ZA (1) ZA202001568B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3005966T3 (en) * 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates
IL316413A (en) * 2022-05-04 2024-12-01 Oak Hill Bio Ltd Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
DE3854842T2 (de) 1988-04-12 1996-06-13 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
AU4238493A (en) 1992-05-08 1993-12-13 Thomas Jefferson University IGF-1 analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AU2002239560B2 (en) * 2000-11-28 2006-03-02 Premacure Ab Determination of risk and treatment of complications of prematurity
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
" EVALUATION OF RHIGF-1/RHIGFBP-3 TO ESTABLISH AND MAINTAIN PHYSIOLOGICAL INTRAUTERINE SERUM IGF-1, European Society for Developmental Perinatal and Paediatric Pharmacology Congress, Leuven, 21-23 Jun, 2017年, 発行日, https://www.esdppp.org/app/download/10920635152/Archdischild-2017-esdppp.pdf?t=1575614335
Growth Horm IGF Res, 2017年08月31日, 発行日, Vol. 36, pp. 44-51
IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity, ClinicalTrials.gov ID NCT01096784, V25 (2017-, 2017年, 掲載日, https://clinicaltrials.gov/study/NCT01096784?tab=history&a=25#version-content-panel
J Pharmacokinet Pharmacodyn (2014) 41:S12, M-013, 2014年, 発行日
Pediatric Research, Volume 81, Number 3, March 2017, pp.504-510, Supplementary information, 2017年, 発行日
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants, PipelineReview.com, 2016年06月30日, 発行日, https://pipelinereview.com/index.php/2016063061758/Proteins-and-Peptides/Shire-Announces-Top-Line-Results-for-Phase-2-Trial-of-SHP607-in-Extremely-Premature-Infants.html
新医薬品の臨床評価に関する一般指針について, 平成四年六月二九日, 薬新薬第四三号, 厚生省薬務局新医薬品, 1992年, 発行日

Also Published As

Publication number Publication date
WO2019051474A1 (en) 2019-03-14
EP4663184A3 (en) 2026-03-18
EA202090705A1 (ru) 2020-06-11
IL273174A (en) 2020-04-30
PH12020500489A1 (en) 2021-02-22
EP4663184A2 (en) 2025-12-17
US20220088132A1 (en) 2022-03-24
MY204825A (en) 2024-09-18
UA128690C2 (uk) 2024-10-02
ZA202001568B (en) 2023-09-27
US20190151411A1 (en) 2019-05-23
AU2018328827B2 (en) 2024-07-25
CA3075482A1 (en) 2019-03-14
KR20200097679A (ko) 2020-08-19
MX2020002744A (es) 2020-10-01
EP3681602B1 (en) 2026-04-15
AU2018328827A1 (en) 2020-04-02
SG11202002088TA (en) 2020-04-29
BR112020004760A2 (pt) 2020-09-15
CN111432881A (zh) 2020-07-17
CO2020004244A2 (es) 2020-05-29
JP2025114869A (ja) 2025-08-05
AU2024227601A1 (en) 2024-11-14
IL273174B2 (en) 2024-12-01
IL273174B1 (en) 2024-08-01
AU2024227601B2 (en) 2026-04-23
MX421623B (es) 2025-03-14
JP2023145646A (ja) 2023-10-11
PE20201166A1 (es) 2020-10-28
EP3681602A1 (en) 2020-07-22
US20240415927A1 (en) 2024-12-19
CL2020000597A1 (es) 2020-12-04
JP2020533344A (ja) 2020-11-19
ECSP20055797A (es) 2020-10-30

Similar Documents

Publication Publication Date Title
JP2025114869A (ja) 慢性肺疾患を治療するための方法および組成物
TWI912393B (zh) 適用於新生兒的組成物
US9463222B2 (en) Methods for treatment of complications of prematurity comprising administration of IGF-I and IGFBP-3
EP1402266B1 (en) Reducing RISK OF COMPLICATIONS OF PREMATURITY
EA044079B1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
HK40033881A (en) Methods and compositions for treating chronic lung diseases
EA049095B1 (ru) Композиции, подходящие для применения у новорожденных
HK40099225B (en) Compositions suitable for use in neonates
HK40099225A (en) Compositions suitable for use in neonates

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210325

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230911

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231006

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250924

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260204

R150 Certificate of patent or registration of utility model

Ref document number: 7819893

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150